First Time Loading...

Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 1.405 USD -3.1% Market Closed
Updated: Jun 10, 2024

Spero Therapeutics Inc
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Spero Therapeutics Inc
Note Receivable Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Spero Therapeutics Inc
NASDAQ:SPRO
Note Receivable
$23.2m
CAGR 3-Years
326%
CAGR 5-Years
139%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Spero Therapeutics Inc's Note Receivable?
Note Receivable
23.2m USD

Based on the financial report for Mar 31, 2024, Spero Therapeutics Inc's Note Receivable amounts to 23.2m USD.

What is Spero Therapeutics Inc's Note Receivable growth rate?
Note Receivable CAGR 5Y
139%

The average annual Note Receivable growth rates for Spero Therapeutics Inc have been 326% over the past three years , 139% over the past five years .